Physician profile
Benjamin Tran
NPI 1902609142
$918.91
in general payments reported to CMS, 2019-2025
24 companies · $919 in 2025
The $919 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.74 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Genzyme Corporation | $67.33 | 2025 | |
| Incyte Corporation | $66.21 | 2025 | Monjuvi, Jakafi, Zynyz |
| Astrazeneca Pharmaceuticals Lp | $60.83 | 2025 | Imfinzi, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $57.80 | 2025 | |
| Daiichi Sankyo INC. | $56.51 | 2025 | Datroway, Enhertu |
| Boston Scientific Corporation | $54.10 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Iovance Biotherapeutics, INC. | $44.60 | 2025 | Amtagvi |
| Taiho Oncology, INC. | $33.31 | 2025 | |
| Janssen Biotech, INC. | $33.29 | 2025 | Darzalex |
| Ipsen Biopharmaceuticals, INC | $32.85 | 2025 | Somatuline Depot, Onivyde |
| Lilly USA, LLC | $32.27 | 2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $31.59 | 2025 | Iclusig |
| Pharmaessentia USA Corporation | $29.07 | 2025 | Besremi |
| Eisai INC. | $28.79 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.55 | 2025 | |
| Puma Biotechnology, INC. | $28.21 | 2025 | |
| Aveo Pharmaceuticals, INC. | $27.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.78 | 2025 | |
| Agios Pharmaceuticals, INC. | $24.96 | 2025 | Pyrukynd |
| Pfizer INC. | $23.48 | 2025 | |
| Geron Corporation | $22.65 | 2025 | Rytelo |
| Sobi, INC | $20.64 | 2025 | |
| Adc Therapeutics America, INC. | $18.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.